Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.
Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.
Results 61 - 70 of 152